Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

NetScientific appoints Prof. Stephen Smith as NED

17 Feb 2016 07:00

RNS Number : 2646P
NetScientific PLC
17 February 2016
 

NetScientific plc

 

NetScientific appoints Professor Stephen Smith as Non-Executive Director

 

London, UK - 17 February 2016 - NetScientific plc ("NetScientific" or the "Group", AIM: NSCI), the transatlantic biomedical and healthcare technology group, appoints Professor Stephen Smith as Non-Executive Director, with effect from today. Professor Smith will also join both the audit and remuneration committees.

Stephen has held senior leadership roles in the NHS and academia. He has had a long and distinguished career as a clinician scientist, Head of Department, Dean and CEO with the Medical Research Council, University of Cambridge, Imperial College, London and Imperial College Healthcare NHS Trust.

He was responsible for the largest merger in the NHS, the creation of the UK's first Academic Health Science Centre in 2007. The merger brought together four London based NHS Trusts and ultimately led to the creation of Imperial College Healthcare NHS Trust, where Stephen served for four years as the first CEO. He also retained his position as Dean of the Faculty of Medicine at Imperial College, London and was responsible for facilitating the commercialisation of life sciences and healthcare.

During his career, Stephen has spun two companies out of Cambridge - Metris Therapeutics Ltd and GNI Group Ltd. GNI was established as a start up in Japan in 2001 and successfully achieved an Initial Public Offering (IPO) on the Tokyo Stock Exchange six years later.

Stephen has extensive non-executive experience serving on the Boards of the National Healthcare Group Singapore which developed integrated care through nine polyclinics. In Australia, he was on the Board of the Royal Melbourne Hospital and the Victorian Comprehensive Cancer Centre, a $1billion project to create a fully integrated cancer care facility that brings together an integrated research, service and education offering to four million patients in Victoria.

Commenting on the appointment, Sir Richard Sykes, Chairman of NetScientific said: "Stephen's impressive leadership experience in mergers and commercialisation internationally further strengthens the Group. We look forward to welcoming Stephen to the team as we continue to build our subsidiary companies towards developing new technologies and concepts in healthcare management and diagnostics to improve patient care and outcomes."

 

Other than the information provided below, which is being disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies, there is no further information required to be disclosed pursuant to this rule. Stephen Kevin Smith, aged 64 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships

Past Directorships

StephenKSmith Ltd

London Genetics Limited

GNI (UK) Limited

The Nuffield Trust for Research and Policy Studies in Health Services

Metris Therapeutics Limited

 

I C Consultants Limited

 

 

- Ends -

 

Contact Details

 

NetScientific

François R. Martelet, M.D., CEO

 

 

Tel: +44 (0)20 3514 1800

 Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook / Rosanna Forrest

Tel: +44 (0)20 7457 2020 Email: netscientific@instinctif.com

 

 

 

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.

For more information, please visit the website at www.netscientific.net. 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADGGDDXGBBGLL
Date   Source Headline
6th Jan 20167:00 amRNSGlycotest Inc. appoints medical advisory board
4th Jan 20167:00 amRNSWANDA signs contract with HRS
16th Dec 20157:00 amRNSLawrence Cohen appointed as CEO of Glycotest Inc.
14th Dec 20157:00 amRNSAppointment of Gene Walther as Vortex CEO
3rd Dec 20157:00 amRNSProAxsis' ProteaseTagT research update
30th Nov 20157:00 amRNSProAxsis presents data to validate its immunoassay
16th Nov 20157:00 amRNSIssue of Equity
11th Nov 20157:00 amRNSHolding(s) in Company
10th Nov 20157:00 amRNSGrant of Options
6th Nov 201512:14 pmRNSResult of General Meeting
3rd Nov 20154:29 pmRNSHolding(s) in Company
21st Oct 20151:52 pmRNSPosting of Circular
1st Oct 20157:00 amRNSProposed Placing and Fund Raising to raise c.£20m
1st Oct 20157:00 amRNSHalf Yearly Report
18th Sep 20157:00 amRNSDivestment of Shareholding in Frontier BioSciences
16th Sep 20151:01 pmRNSHolding(s) in Company
15th Sep 20157:00 amRNSVortex BioSciences granted critical patent
9th Sep 20151:00 pmRNSSteve Curd appointed as CEO of Wanda
7th Aug 20157:00 amRNSDivestment of non-core assets to align portfolio
4th Aug 20157:00 amRNSProAxsis launches first-in-class ProteaseTag test
15th Jul 20157:00 amRNSKey patent granted for Glucosense's technology
22nd Jun 20151:19 pmRNSResults of Annual General Meeting
22nd Jun 20157:00 amRNSAGM Statement
5th Jun 20155:46 pmRNSNotification of Major Interest in Shares
5th Jun 20155:42 pmRNSNotification of Major Interest in Shares
5th Jun 20155:38 pmRNSNotification of Major Interest in Shares
5th Jun 20152:00 pmRNSNotification of Major Interest in Shares
5th Jun 20152:00 pmRNSNotification of Major Interest in Shares
28th May 201512:02 pmRNSPDS Biotechnology reports positive Phase I results
18th May 20157:00 amRNSNotice of AGM and Annual Report & Accounts
15th May 20157:00 amRNSCapital Markets Day
11th May 20157:00 amRNSDr. François R. Martelet appointed as CEO
7th May 20157:00 amRNSNetScientific invests in Neumitra
1st May 20157:00 amRNSNetScientific Forms New Digital Health Company
29th Apr 20159:00 amRNSNetScientific Capital Markets Day
1st Apr 20157:00 amRNSChange of Adviser
24th Mar 20157:00 amRNSSignificant Progress in core Portfolio Companies
20th Mar 20152:00 pmRNSNotice of Full Year Results
26th Feb 201510:07 amRNSAppointment of Non-Executive Director
16th Jan 20156:19 pmRNSDirectorate Change
7th Jan 20151:04 pmRNSNetScientific teams up with KU Leuven
7th Jan 20151:04 pmRNSNetScientific invests in DName-iT
15th Dec 20147:00 amRNSNetScientific invests in PDS Biotechnology
11th Dec 20147:00 amRNSNetScientific enters into alliance with Healthbox
8th Dec 20147:00 amRNSNetScientific invests in Breakout Labs' portfolio
17th Nov 20143:36 pmRNSHolding(s) in Company
17th Nov 20141:26 pmRNSHolding(s) in Company
3rd Oct 20147:00 amRNSSubsidiary, Glycotest collaboration with Oncimmune
23rd Sep 20147:00 amRNSHalf Yearly Report
17th Sep 20142:00 pmRNSNotice of Half Yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.